Cannabis Sector Sees Significant Gains Following FDA Announcement on CBD Enforcement
The cannabis industry experienced a significant surge in the past week, with shares of major players such as Tilray, Canopy Growth, and Curaleaf increasing substantially. The upward momentum is attributed to a recent announcement by the FDA, which stated it will not pursue enforcement action against certain hemp-derived oral CBD products.
The FDA’s decision follows President Trump’s executive order in December, which moved marijuana from Schedule I to Schedule III classification under federal drug regulations. The FDA’s announcement also comes as part of a four-part meeting series with industry representatives to address CBD compliance and enforcement strategies.
Tilray, a leading cannabis company, saw its shares climb 6.7% on Thursday, making it one of the top performers in the sector. Canopy Growth, another major player, advanced 2.6% during the same period. Curaleaf, a domestically-focused cannabis company, experienced the most impressive gains, surging 8.4% on Thursday.
The cannabis sector’s ETF, AdvisorShares Pure US Cannabis, also saw significant gains, climbing 4.6% on Thursday and 16% across the week. This marks the ETF’s strongest weekly gain since December.
Industry experts note that while the FDA’s policy shift is a positive step, it falls short of establishing a comprehensive framework for the wider cannabis marketplace. They urge Congressional legislative action to address the industry’s challenges, including limited banking services, stock exchange listing restrictions, and interstate trade barriers.
The FDA’s announcement and the cannabis sector’s gains come as the industry continues to navigate the complexities of federal regulations. The sector’s growth is expected to be driven by increasing consumer demand for CBD products and the potential for federal policy changes that could enable cross-state commerce for cannabis operations.
